Share-based Payment Arrangement, Expense of Protara Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Protara Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2024.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $931,000, a 36% decline year-over-year.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $4,673,000, a 23% decline year-over-year.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,092,000, a 8.9% decline from 2022.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,688,000.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $943,000, a 72% decline from 2018.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Protara Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $4,673,000 $931,000 -$516,000 -36% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $5,189,000 $1,064,000 -$554,000 -34% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $5,743,000 $1,226,000 -$349,000 -22% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $6,092,000 $1,452,000 +$22,000 +1.5% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2024 2023 FY
Q3 2023 $6,070,000 $1,447,000 +$10,000 +0.7% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $6,060,000 $1,618,000 -$324,000 -17% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $6,384,000 $1,575,000 -$304,000 -16% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $6,688,000 $1,430,000 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $1,437,000 -$1,279,000 -47% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $1,942,000 -$1,056,000 -35% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $1,879,000 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q3 2021 $2,716,000 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $2,998,000 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q4 2019 $943,000 $34,000 -$816,000 -104% 01 Oct 2019 31 Dec 2019 10-K 20 Mar 2020 2019 FY
Q3 2019 $1,759,000 $96,000 -$808,000 -89% 01 Jul 2019 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $2,567,000 $101,000 -$821,000 -89% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $3,388,000 $780,000 -$41,000 -5% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $3,429,000 $782,000 +$14,000 +1.8% 01 Oct 2018 31 Dec 2018 10-K 20 Mar 2020 2019 FY
Q3 2018 $3,415,000 $904,000 +$157,000 +21% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $3,258,000 $922,000 +$55,000 +6.3% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $3,203,000 $821,000 -$24,000 -2.8% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $3,227,000 $768,000 -$76,000 -9% 01 Oct 2017 31 Dec 2017 10-K 13 Mar 2019 2018 FY
Q3 2017 $3,303,000 $747,000 +$60,000 +8.7% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $3,243,000 $867,000 -$79,000 -8.4% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $3,322,000 $845,000 -$21,000 -2.4% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $3,343,000 $844,000 +$174,000 +26% 01 Oct 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
Q3 2016 $3,169,000 $687,000 +$76,000 +12% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $3,093,000 $946,000 +$470,000 +99% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $2,623,000 $866,000 +$459,000 +113% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $2,164,000 $670,000 +$445,000 +198% 01 Oct 2015 31 Dec 2015 10-K 14 Mar 2018 2017 FY
Q3 2015 $1,719,000 $611,000 +$426,000 +230% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $1,293,000 $476,000 +$444,000 +1388% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $849,000 $407,000 +$390,000 +2294% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $459,000 $225,000 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
Q3 2014 $185,000 +$164,000 +781% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $32,000 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $17,000 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015 2015 Q1
Q3 2013 $21,000 01 Jul 2013 30 Sep 2013 10-Q 25 Nov 2014 2014 Q3

Protara Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $6,092,000 -$596,000 -8.9% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2024 2023 FY
2022 $6,688,000 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2019 $943,000 -$2,486,000 -72% 01 Jan 2019 31 Dec 2019 10-K 20 Mar 2020 2019 FY
2018 $3,429,000 +$202,000 +6.3% 01 Jan 2018 31 Dec 2018 10-K 20 Mar 2020 2019 FY
2017 $3,227,000 -$116,000 -3.5% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2019 2018 FY
2016 $3,343,000 +$1,179,000 +54% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
2015 $2,164,000 +$1,705,000 +371% 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2018 2017 FY
2014 $459,000 +$304,000 +196% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $155,000 +$45,000 +41% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
2012 $110,000 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.